ASH 2017 | Update on immunotherapy trials for AML from ASH 2017: bispecific DARTs, CAR T-cells and ADCs
Immunotherapy for acute myeloid leukemia (AML) is an exciting area, with clinical trials, including those that are first-in-human, showing promising results. Here, Marina Konopleva, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an update on a range of these trials, including response rates and toxicities. Dr Konopleva covers the trial of the bispecific CD3xCD123 DART, flotetuzumab (NCT02152956); a next-generation CD123-targeting CAR T-cell therapy (NCT02159495); and the antibody-drug conjugate IMG9N77, which targets CD33 (NCT02674763). This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Get great new content delivered to your inboxSign up